Last update Jan. 1, 2021
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Mometasone Furoate is also known as
Mometasone Furoate in other languages or writings:
Mometasone Furoate belongs to these groups or families:
Main tradenames from several countries containing Mometasone Furoate in its composition:
|Oral Bioavail.||0.1 - 1||%|
|T½||4.5 - 5.6||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Corticosteroid for topical cutaneous, intranasal or inhaled application.
Indicated in the treatment of asthma, allergic rhinitis and atopic dermatitis, psoriasis and contact eczema.
Authorized use in Pediatrics from 3 years (rhinitis) and 12 years (asthma).
At the date of this last update we did not find published data on its excretion in breast milk.
Mometasone furoate is poorly absorbed after inhalation, intranasal use, and topical application (< 1%).
Its pharmacokinetic characteristics (low systemic absorption, moderately elevated molecular weight, high plasma protein binding, high pKa and large volume of distribution, make it very unlikely its excretion into breast milk in significant amounts.
Its very low oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk.
Several medical societies, experts and expert consensus, consider the use of this medication to be safe and compatible with breastfeeding (Middleton 2020, National Asthma EPP 2004).
When used for treatment of eczema or dermatitis of the nipple, it should be preferred a lower-potency steroid together with application just after a feed in order to let the medication has disappeared before the next meal. Otherwise, wipe-out excess of cream by using a cotton gauze and avoid a continuous use for longer than one week.
Reportedly, one case of mineral-steroid toxicity occurred after a prolonged use on the nipple (De Stefano 1983).
It is advisable to avoid the application to the nipple of creams, gels and other topical products containing paraffin (mineral oil) so that the infant does not absorb them (Concin 2008, Noti 2003).